Moses I Goddard

6361771, Mar 26, 2002

Apr 5, 2000

09/543119

Weng Tao - Lincon RI
David H. Rein - Cambridge MA
Brenda J. Dean - Cumberland RI
Paul F. Stabila - Coventry RI
Moses B.I. Goddard - Tiverton RI

Neurotech S.A. - Evry

A61K 4800

424 9321, 4353201, 435325, 435455, 435366, 435371, 6048901, 604 43, 604 93

ARPE-19 cells were evaluated as a platform cell line for encapsulated and un-encapsulated cell-based delivery technology. ARPE-19 cells were found to be hardy (the cell line is viable under stringent conditions, such as in central nervous system or intra-ocular environment); can be genetically modified to secrete the protein of choice; has a long life span; is of human origin; has good in vivo device viability; delivers efficacious quantity of growth factor; triggers no or low level host immune reaction, and is non-tumorigenic.

20070071734, Mar 29, 2007

Oct 3, 2006

11/543015

Weng Tao - Lincoln RI, US
David Rein - Cambridge MA, US
Brenda Dean - Cumberland RI, US
Paul Stabila - Coventry RI, US
Moses Goddard - Tiverton RI, US

A61K 48/00
A61F 2/02

424093210, 424423000, 424427000

ARPE-19 cells were evaluated as a platform cell line for encapsulated and unencapsulated cell-based delivery technology. ARPE-19 cells were found to be hardy (the cell line is viable under stringent conditions, such as in central nervous system or intra-ocular environment); can be genetically modified to secrete the protein of choice; have a long life span; are of human origin; have good in vivo device viability; deliver efficacious quantity of growth factor; trigger no or low level host immune reaction, and are non-tumorigenic.

20090269319, Oct 29, 2009

Jul 8, 2009

12/499403

Weng Tao - Lincoln RI, US
David H. Rein - Cambridge MA, US
Brenda J. Dean - Cumberland RI, US
Paul F. Stabila - Coventry RI, US
Moses B.I. Goddard - Tiverton RI, US

NEUROTECH USA, INC. - Lincoln RI

A61K 45/00
A61P 35/00

424 937

ARPE-19 cells were evaluated as a platform cell line for encapsulated and unencapsulated cell-based delivery technology. ARPE-19 cells were found to be hardy (the cell line is viable under stringent conditions, such as in central nervous system or intra-ocular environment); can be genetically modified to secrete the protein of choice; have a long life span; are of human origin; have good in vivo device viability; deliver efficacious quantity of growth factor; trigger no or low level host immune reaction, and are non-tumorigenic.

20090269389, Oct 29, 2009

Jul 7, 2009

12/498737

Weng Tao - Lincoln RI, US
David H. Rein - Cambridge MA, US
Brenda J. Dean - Cumberland RI, US
Paul F. Stabila - Coventry RI, US
Moses B.I. Goddard - Tiverton RI, US

NEUROTECH USA, INC. - Lincoln RI

A61P 9/00
C12N 5/08
A61P 43/00

424425, 435366, 424424

ARPE-19 cells were evaluated as a platform cell line for encapsulated and unencapsulated cell-based delivery technology. ARPE-19 cells were found to be hardy (the cell line is viable under stringent conditions, such as in central nervous system or intra-ocular environment); can be genetically modified to secrete the protein of choice; have a long life span; are of human origin; have good in vivo device viability; deliver efficacious quantity of growth factor; trigger no or low level host immune reaction, and are non-tumorigenic.

56432860, Jul 1, 1997

Jun 24, 1994

8/265242

Nicholas Warner - Belmont MA
Moses Goddard - Tiverton RI
John Mills - Wakefield RI

CytoTherapeutics, Inc. - Providence RI

A61B 1900
A61B 1756

606130

The present invention is directed to microdrive apparatus useful in human stereotactic surgery. Such apparatus permits safe and accurate placement of a surgical instrument, such as a cannula, into a portion of the central nervous system, e. g. the brain and spinal cord, of a patient by simple mechanical operation.

61798266, Jan 30, 2001

Oct 29, 1996

8/741228

Patrick Aebischer - Barrington RI
Moses Goddard - Tiverton RI
John G. Moldauer - Brooklyn NY
Paul J. Mulhauser - New York NY
Anne M. Rathbun - Providence RI
Paul R. Sanberg - Greeenwich RI
Alfred V. Vasconcellos - Cranston RI
Nicholas F. Warner - Belmont MA

Brown University Research Foundation - Providence RI

A61M 3100

604522

Implantable therapy systems are disclosed for the local and controlled delivery of a biologically active factor to the brain, spinal cord and other target regions of a subject suffering from a dibilatating condition. The method of the invention involves surgically exposing an insertion site, generally located above a predetermined treatment site (12), in a patient. A cannula (20), having an obturator (30) or dilator (104) positioned therein, is inserted at the insertion site, defining a pathway to the treatment site. In some instances, the cannula can be inserted along the path of a guidewire (102) previously positioned at the treatment site. The cannula (20) is preferably a low friction polymeric material such as polytetrafluoroethylene. The cannula (20) generally has an open proximal end for receiving the obturator (30) or dilator (104), and an open distal end, preferably a tapered end, for delivery of neurologically active factors to the treatment site (12). The obturator (30) is then removed from the cannula (20), and a biocompatible tethered vehicle (40) containing a biologically active material is inserted into the cannula along the passageway.

54877393, Jan 30, 1996

Jun 2, 1995

8/459815

Patrick Aebischer - Barrington RI
Moses Goddard - Tiverton RI
John G. Moldauer - Brooklyn NY
Paul J. Mulhauser - New York NY
Anne M. Rathbun - Providence RI
Paul R. Sanberg - Greenwich RI
Alfred V. Vasconcellos - Cranston RI
Nicholas F. Warner - Belmont MA

Brown University Research Foundation - Providence RI

A61K 922

6048901

Implantable therapy systems are disclosed for the local and controlled delivery of a biologically active factor to the brain, spinal cord and other target regions of a subject suffering from a debilitating condition. The method of the invention involves surgically exposing an insertion site, generally located above a predetermined treatment site (12), in a patient. A cannula (20), having an obturator (30) or dilator (104) positioned therein, is inserted at the insertion site, defining a pathway to the treatment site. In some instances, the cannula can be inserted along the path of a guidewire (102) previously positioned at the treatment site. The cannula (20) is preferably a low friction polymeric material such as polytetrafluoroethylene. The cannula (20) generally has an open proximal end for receiving the obturator (30) or dilator (104), and an open distal end, preferably a tapered end, for delivery of neurologically active factors to the treatment site (12). The obturator (30) is then removed from the cannula (20), and a biocompatible tethered vehicle (40) containing a biologically active material is inserted into the cannula along the passageway.

55541488, Sep 10, 1996

May 26, 1995

8/453571

Patrick Aebischer - Barrington RI
Paul C. DiCesare - Norwalk CT
Moses Goddard - Tiverton RI
Paul J. Mulhauser - New York NY

Brown University Research Foundation - Providence RI

A61K 922

6048901

Refillable immunoisolatory neurological therapy devices for local and controlled delivery of a biologically active factor to the brain of a patient. The devices include a cell chamber adapted for infusion with nsecretory cells and having at least one semipermeable or permselective surface across which biologically active factors secreted by the cells can be delivered to the brain. The devices also include means for introducing secretory cells into the cell chamber, and means for renewing the cells or cell medium.